Skip to content
White_Message

02/12/2024 – We are currently experiencing issues with our digital ‘contact us’ forms. We appreciate your patience and understanding as we work to resolve this. For urgent matters, please contact us via 0333 103 9499. Alternatively, please email us at generalenquries@sciensus.com with your Full Name, DOB, Postcode and the details of your query.

Sciensus names Christian Tucat as Chief Executive Officer

Sciensus, a leading pan European, life sciences business, providing patient access, engagement and insight solutions, is pleased to announce the appointment of Christian Tucat as Chief Executive Officer. Mr Tucat succeeds Darryn Gibson, who has led the organization for the past six years.

Mr Tucat brings 25 years of experience in the life sciences sector, primarily focusing on helping pharmaceutical companies deliver lifesaving drugs and therapies to patients. Prior to joining Sciensus, Mr Tucat held multiple senior roles at Syneos Health, including Chief Business Officer, President of Syneos One and President of Real-World Evidence Solutions. His career also includes leadership positions at INC Research, PRA International, Eli Lilly, and GlaxoSmithKline.

At Syneos, Mr Tucat built a market-leading real world evidence business and founded and led Syneos One, a leader in fully integrated asset development, designed to accelerate asset value and time to market. In his last role as Chief Business Officer, Mr Tucat led Syneos Health’s global growth strategy across Clinical, Medical Affairs and Commercial services.

Christian Tucat said: “I am thrilled to be joining the tremendously talented team at Sciensus and to have the opportunity to build on the success that has been achieved. Sciensus’ focus on helping patients achieve better healthcare outcomes, along with its strong partnerships with pharmaceutical, private medical insurers and healthcare provider organisations, creates a unique opportunity to leverage valuable insights and make a significant impact on patient care.

I look forward to working with the exceptional team of colleagues, the Board, patient advocacy groups, health care providers/NHS and pharma partners to shape this important next chapter, as we continue to put patients at the centre of what we do. A key focus will be to further develop Sciensus’ adherence and digital insight capabilities and expand its European reach.”

Peter Nicklin, Chairman of Sciensus said:  “Over the past six years Sciensus has transformed into a leading technology-driven life science services company serving our chronic, rare disease and cancer customers. I am delighted that Christian is joining Sciensus and have every confidence that under his leadership we will continue to build a world class company that improves patient health outcomes.”

Torsten Winkler, Partner at Vitruvian Partners and Doug Oppenheim, Partner, at Palladian Investment Partners, jointly commented: “We are delighted to welcome Christian as CEO. Christian brings tremendous global experience and energy to Sciensus as the company is expanding its capabilities to support more patients to make the most of their medicines.

Notes to Editors:

For more information, please contact Sciensus@teneo.com

About Sciensus:

Sciensus is a leading European provider of patient access, engagement and insight solutions. We connect over 250,000 patients with their medicines at any point in time, and support and empower them to get their best outcomes.

For over 30 years we have helped chronic, rare disease and cancer patients across Europe in over 50 therapy areas.

With over 70 million patient interactions to date, we are uncovering data and generating new insights to help patients make the most of their medicines and keep their lives on track.

We partner with over 1,250 clinics and hospitals, and European life science companies, providing them with valuable insights and real-world evidence.